Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicorette and NASCAR

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline Consumer Healthcare broadens its NASCAR collaboration with an agreement to rename the 2006 "Busch Series" race at Atlanta Motor Speedway the "Nicorette 300" under a sponsorship announced June 26. The Busch series "is the second most popular form of motorsports in the U.S." and an opportunity to reach "core NASCAR fans," according to the firm's Smoking Control Products VP Bill Slivka. GSK announced its deal with NASCAR in January (1"The Tan Sheet" Jan. 31, 2005, In Brief)...

You may also be interested in...



NASCAR promotes quitting

NASCAR vehicles will feature GlaxoSmithKline smoking cessation products including Nicorette nicotine gum, NicoDerm CQ patches andCommit lozenges under sponsorship agreement, GSK announces Jan. 27. Nicorette Fresh Mint will be featured on Casey Mears' car for the first time at the Golden Corral 500 on March 20. GSK promotes the NRT gum as "the first quit-smoking gum that tastes like real gum." Glaxo will support the partnership with advertising and exhibits at the 2005 NEXTEL Cup. Until last year, the race was sponsored by Winston cigarettes...

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.

Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel